05.25.23 -- Astellas Exec: Responding To A Clinical Hold

Most of the Top 10 pharmaceutical companies and many large biotech companies today get a portion of their preclinical/clinical research, drug development, and/or manufacturing done in India. While a low price is the initial attraction, there are additional factors that can be more meaningful.

Read about the continuous evaluation and varying opinion regarding the strategic resourcing models employed within the biopharmaceutical sector today.

A financial project analyst (FPA) plays a critical role in clinical trial supply and budget management. Explore how sponsors can benefit from having this specialist on their supply partner's team.

The stability challenges of many biologics require lyophilization to improve product stability, increasing the demand for CDMOs with expertise, scalable development, and manufacturing solutions.

Learn about a proven, robust technology capable of providing customers with the flexibility to build a range of standardized trials — from simple Phase 1 to complex Phase 3 studies.

Improve your eCOA data collection and clinical trial efficiency with Kayentis and ClinOne's combined solution covering eCOA, virtual visits, consent management, patient engagement, and more.

Ha Tran, executive medical director at Astellas Pharma, explains the cause of the clinical hold and the future of the program now that the hold has been lifted.

Address common questions concerning the IVDR product classification system and how to comply with the new clinical evidence and performance expectations.

See how a clinical-stage biotechnology company was able to successfully file its IND submissions and complete CSR publishing tasks, in addition to creating a synchronized team.

Discover how having all sites use a central IRB can build efficiencies and results in significant resource savings for everyone involved in the research study and improves human subject protections.

See what industry organizations are saying about trial transparency, regulations by region, what penalties are on the books, and whether they are enforced.

Learn how the recent developments in market access and regulatory rules in Japan and South Korea have paved the way for expansion in Asia.

IQVIA offers a complete approach that combines safety, regulatory, quality, and medical information to transform and sustain compliance.